Bill targets aggressive online sales
This article was originally published in The Rose Sheet
The use of "negative-option" schemes would be regulated under legislation introduced May 19 by Sen. Jay Rockefeller, D-W.Va. Negative-option strategies, in which marketers lure consumers with "free trial" offers and then charge their credit cards, are often used by online vendors of weight-loss "supplements" and have attracted Federal Trade Commission attention. S. 13386, the "Restore Online Shoppers' Confidence Act," would also prohibit marketers from using misleading post-transaction ads and from transferring consumer billing information to third-party sellers. The legislation follows a November 2009 report on aggressive sales tactics and awaits action by the Senate Commerce, Science and Transportation Committee
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.